Cardiovascular Animation Circulatory Animations

Factors Other Than Central Sleep Apnea May Contribute To Poor Sleep Quality In Heart-Failure Patients
A study in the Jan. 1 issue of the journal Sleep demonstrates that the frequent arousals from sleep that occur in heart failure patients with central sleep apnea (CSA) may reflect the presence of another underlying arousal disorder rather than being a defensive mechanism to terminate apneas.

Gene Therapy Reversed Heart Damage In Heart Failure
Long-term gene therapy resulted in improved cardiac function and reversed deterioration of the heart in rats with heart failure, according to a recent study conducted by researchers at Thomas Jefferson University's Center for Translational Medicine. The study was published online in Circulation.

Flu Season Is Here: How To Detect Symptoms Of Viral Myocarditis In Children And Young Adults
Influenza, strep throat and the common cold afflict many people during the winter months, particularly in children and young adults, yet there is one often undiagnosed viral condition that can be far deadlier then these common viruses. Viral myocarditis is a sometimes fatal infection that inflames the myocardium, the thick muscular layer of the heart wall, and is the most common cause of heart failure in otherwise healthy children and young adults.

Heart Attack Hospitalizations Drop After US City Bans Smoking, CDC
In the US city of Pueblo in the state of Colorado there has been a sharp drop in the number of hospital admissions for heart attacks following the introduction of a law that made it illegal to smoke in public spaces and workplaces. And the drop was steady for three years, said the US Center for Disease Control and Prevention (CDC).

New Plans To Improve Prevention Of Vascular Disease, UK
New plans to improve the prevention and management of patients with vascular disease were announced today by Health Minister Edwina Hart. Mrs Hart said that a group of clinicians will review current provision of vascular risk management and assessment in Wales and recommend a future model to reduce the number of people developing the disease.

Effectiveness Of Prenatal Diagnosis Of Congenital Heart Defects, South Australia
This population analysis reports on the efficacy of prenatal diagnosis of congenital heart disease (CHD) using fetal echocardiography and South Australia's current obstetric screening program. Being a sensitive and specific tool for detecting CHD, fetal echocardiography is a much more accurate means for detecting structural defects in fetal hearts as compared to the routine obstetric screenings.

Phase IIa Clinical Trial Results Relating To CK-1827452 In Patients With Ischemic Cardiomyopathy And Angina
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today top-line results from a Phase IIa clinical trial evaluating the safety of CK-1827452 in patients with ischemic cardiomyopathy and angina.  The primary safety endpoint was defined as stopping an exercise test during treatment with CK-1827452 (versus placebo) due to unacceptable angina at an earlier exercise stage than at baseline.

Genetic Variation In Young Heart Attack Patients Results In Anticlotting Drug Clopidogrel Being Less Effective
If a young heart attack patient (under 45 years of age) has a certain genetic variation, the anticlotting drug clopidogrel is less effective in that person and they are much more likely to die, have another heart attack, require urgent repeat coronary intervention or have stent thrombosis.

Innovative Gene Therapy Approach To Prevent Amputations In Patients Suffering Severe Peripheral Artery Disease
Cardiologists at Rush University Medical Center are studying an investigational medication to prevent amputations in patients suffering the most severe form of peripheral arterial disease. The study involves use of a highly innovative gene therapy approach to promote new blood vessel growth in the legs of patients with critical limb ischemia.

X-GEN Pharmaceuticals Receives FDA Approval For AcetaZOLAMIDE For Injection USP
X-GEN Pharmaceuticals announced that it will begin marketing Acetazolamide for Injection USP. The product is AP rated and equivalent to Diamox(R)(1) by Duramed Pharmaceuticals.

Sucampo Initiates Phase 1 Study Of SPL-017 For Peripheral Arterial Disease
Sucampo Pharma, Ltd., of Japan, a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today announced that it has initiated dosing in a first-in-human clinical safety study of a proprietary prostone, SPL-017, as a potential treatment for peripheral arterial disease (PAD). The randomized, double-blind, placebo-controlled, single-center, single ascending dose study will evaluate the safety and pharmacokinetic profile of SPL-017.

Molecular Insight's Zemiva™ Demonstrates Ability To Significantly Improve Early Diagnosis Of The Chest Pain Patient In The Emergency Department
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that results from a recently completed Phase 2 clinical study (BP-23) suggest that Zemiva, when combined with the standard of care for the diagnostic evaluation of the chest pain patient, significantly improved the detection of cardiac ischemia when compared to the standard of care alone. The improved sensitivity was more than 50% greater (p

Apolipoprotein(a): A Natural Regulator Of Inflammation
In a study to be published in the January 09 issue of Experimental Biology and Medicine, Hoover-Plow and co-workers in seeking to define a role of apo(a) in leukocyte recruitment have identified a novel activity of apo(a) apolipoprotein that may function as a natural and cell specific suppressor of the inflammatory response in vivo. In addition, a mechanism for this novel function of apo(a) was also identified: its selective regulation of cytokine production.

Medistem Files IND For Endometrial Regenerative Cells In Treatment Of Critical Limb Ischemia
Medistem Inc. (OTCBB: MEDS) announced today it has filed an Investigational New Drug (IND) Application with the United States Food and Drug Administration to undertake clinical studies using its proprietary endometrial regenerative cells (ERC) in patients with an advanced form of peripheral artery disease termed "critical limb ischemia.

Two Cardiovascular Proteins Pose A Double Whammy In Alzheimer's
Researchers have found that two proteins which work in tandem in the brain's blood vessels present a double whammy in Alzheimer's disease. Not only do the proteins lessen blood flow in the brain, but they also reduce the rate at which the brain is able to remove amyloid beta, the protein that builds up in toxic quantities in the brains of patients with the disease. The work, described in a paper published online Dec.